Clinical utility of microarrays: current status, existing challenges and future outlook.

摘要: Microarray-based clinical tests have become powerful tools in the diagnosis and treatment of diseases. In contrast to traditional DNA-based that largely focus on single genes associated with rare conditions, microarray-based are ideal for study diseases underlying complex genetic causes. Several microarray based been translated into practice such as MammaPrint AmpliChip CYP450. Additional cancer-related either process FDA review or under active development, including Tissue Tumor Origin p53. All diagnostic testing is ordered by physicians tested a Clinical Laboratories Improvement Amendment-certified (CLIA) reference laboratory. Recently, companies offering consumer emerged. Individuals can order online service providers deliver results directly clients via password-protected secure website. Navigenics, 23andMe deCODE Genetics represent pioneering this field. Although progress these extremely encouraging potential revolutionize recognition common diseases, still their infancy face technical, marketing challenges. article, we which currently approved FDA, well consumer-based testing. We also provide summary challenges strategic solutions development use tests. Finally, present brief outlook future applications.